(R)-methyl 4-(2-(3,3-difluoro-5-formyl-2-oxopyrrolidin-1-yl)ethyl)benzoate | 1544279-30-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-methyl 4-(2-(3,3-difluoro-5-formyl-2-oxopyrrolidin-1-yl)ethyl)benzoate
• 英文别名: methyl 4-[2-[(5R)-3,3-difluoro-5-formyl-2-oxopyrrolidin-1-yl]ethyl]benzoate
• CAS: 1544279-30-2
• 化学式: C₁₅H₁₅F₂NO₄
• 分子量: 311.285
• InChiKey: GGVNNZQENCLXQR-GFCCVEGCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  63.7
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (R)-methyl 4-(2-(3,3-difluoro-5-formyl-2-oxopyrrolidin-1-yl)ethyl)benzoate 、 3-methyl-2-oxo-oct-5-ynyl-phosphonic acid-dimethylester 生成 methyl 4-(2-((5R)-3,3-difluoro-5-((E)-3-hydroxy-4-methylnon-1-en-6-yn-1-yl)-2-oxopyrrolidin-1-yl)ethyl)benzoate
  参考文献：
  名称：

  Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions

  摘要：

  本文公开了公式（I）的化合物以及使用公式（I）的化合物进行治疗的治疗方法，其中L1、L2、L4、R1、R4、R5、R6和s在规范中定义。公式（I）的化合物是EP4激动剂，可用于治疗青光眼、神经病性疼痛和相关疾病。

  公开号：

  US09180116B2
• 作为产物：
  描述：

  (R)-methyl 4-(2-(3,3-difluoro-5-(hydroxymethyl)-2-oxopyrrolidin-1-yl)ethyl)benzoate 、 、 (R)-methyl 7-(3,3-difluoro-5-(hydroxymethyl)-2-oxopyrrolidin-1-yl)heptanoate 以 methanol-dichloromethane 为溶剂， 生成 (R)-methyl 4-(2-(3,3-difluoro-5-formyl-2-oxopyrrolidin-1-yl)ethyl)benzoate
  参考文献：
  名称：

  METHODS, SYSTEMS, AND COMPOSITIONS FOR PROMOTING BONE GROWTH

  摘要：

  本发明涉及一种新型骨组成物，用于局部向骨缺损部位提供治疗剂。治疗剂可以促进骨缺损的修复和/或治疗疼痛、炎症、癌症和感染等病症或疾病。该组成物包括磷酸钙水泥和脱矿骨基质或胶原海绵。该组成物可用于患者的骨缺损部位植入。

  公开号：

  US20160158413A1

文献信息

• [EN] DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS<br/>[FR] COMPOSITIONS DE DIFLUOROLACTAME DESTINÉES À DES MALADIES ET DES AFFECTIONS OSSEUSES MÉDIÉES PAR EP4
  申请人：CAYMAN CHEMICAL CO INC

  公开号：WO2014015246A1

  公开（公告）日：2014-01-23

  Disclosed herein are compositions and methods of treating osteroporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification.

  披露的是通过给予公式(I)化合物的组合物和方法来治疗骨质疏松症、骨折、骨丢失以及增加骨密度，其中组合物包含公式(I)的化合物和药用可接受的载体，其中L1、L2、L4、R1、R4、R5、R6和s按说明书定义。
• DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS
  申请人：Cayman Chemical Company, Inc.

  公开号：US20150174099A1

  公开（公告）日：2015-06-25

  Disclosed herein are compositions and methods of treating osteoporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L 1 , L 2 , L 4 , R 1 , R 4 , R 5 , R 6 , and s are as defined in the specification.

  本文披露了使用式(I)化合物或包含式(I)化合物和药物可接受载体的组合物治疗骨质疏松症、骨折、骨质流失和增加骨密度的方法和组合物。其中，L1、L2、L4、R1、R4、R5、R6和s如规范中所定义。
• DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS
  申请人：Cayman Chemical Company, Inc.

  公开号：US20150175538A1

  公开（公告）日：2015-06-25

  Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L 1 , L 2 , L 4 , R 1 , R 4 , R 5 , R 6 , and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.

  本文公开了式(I)的化合物及使用该化合物的治疗方法，其中L1、L2、L4、R1、R4、R5、R6和s的定义如规范中所述。式(I)的化合物是EP4激动剂，可用于治疗青光眼、神经病性疼痛和相关疾病。
• Difluorolactam compositions for EP4-mediated osteo related diseases and conditions
  申请人：Cayman Chemical Company, Inc.

  公开号：US09440919B2

  公开（公告）日：2016-09-13

  Disclosed herein are compositions and methods of treating osteoporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification.

  本文披露了通过给予式(I)化合物或含有式(I)化合物和药用可接受载体的组合物来治疗骨质疏松症、骨折、骨质丢失和增加骨密度的组合物和方法，其中L1、L2、L4、R1、R4、R5、R6和s如规范中所定义。
• Methods, systems, and compositions for promoting bone growth
  申请人：Cayman Chemical Company, Inc.

  公开号：US10729810B2

  公开（公告）日：2020-08-04

  The present invention relates to novel bone compositions for locally delivering a therapeutic agent to the site of a bone defect. Therapeutic agents may promote repair of the bone defect and/or treat conditions or disorders such as pain, inflammation, cancer, and infection. The compositions include calcium phosphate cements and a demineralized bone matrix or a collagen sponge. The compositions are useful for implantation in a patient at the site of a bone defect.

  本发明涉及用于向骨缺损部位局部输送治疗剂的新型骨组合物。治疗剂可促进骨缺损的修复和/或治疗疼痛、炎症、癌症和感染等疾病。组合物包括磷酸钙骨水泥和脱矿骨基质或胶原海绵。这些组合物可用于植入患者骨缺损部位。